Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
Myriad Genetics (NASDAQ: MYGN) will present 11 new research studies at the National Society of Genetic Counselors 44th Annual Conference on Nov. 7–8, 2025, highlighting oncology and reproductive genetic testing advances.
Featured products include MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen. Myriad will exhibit at booth #317 and share poster presentations on topics such as RNA analysis for VUS interpretation, fetal fraction amplification for early cfDNA screening, prenatal cfDNA detecting maternal colorectal cancer, automated FXN repeat detection, and genetics education and recontact workflows.
Myriad Genetics (NASDAQ: MYGN) presenterà 11 nuovi studi di ricerca alla 44ª conferenza annuale della National Society of Genetic Counselors il 7-8 novembre 2025, evidenziando progressi nei test genetici oncologici e riproduttivi.
I prodotti in evidenza includono MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen e Foresight Carrier Screen. Myriad esporrà allo stand booth #317 e condividerà presentazioni poster su temi quali analisi dell'RNA per l'interpretazione di VUS, amplificazione della frazione fetale per lo screening precoce del cfDNA, cfDNA prenatale che rileva il cancro colorettale materno, rilevazione automatizzata di ripetizioni FXN, e istruzioni sull'educazione genetica e sui flussi di ricontatto.
Myriad Genetics (NASDAQ: MYGN) presentará 11 nuevos estudios de investigación en la 44.ª Conferencia Anual de la National Society of Genetic Counselors los días 7 y 8 de noviembre de 2025, destacando avances en pruebas genéticas oncológicas y reproductivas.
Los productos destacados incluyen MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen y Foresight Carrier Screen. Myriad participará en el stand booth #317 y compartirá presentaciones en cartel sobre temas como análisis de RNA para la interpretación de VUS, amplificación de la fracción fetal para el cribado temprano de cfDNA, cfDNA prenatal que detecta cáncer colorrectal materno, detección automatizada de repeticiones FXN, y educación genética y flujos de recontacto.
Myriad Genetics (NASDAQ: MYGN)는 2025년 11월 7-8일에 열리는 National Society of Genetic Counselors 44번째 연례 컨퍼런스에서 11개의 새로운 연구를 발표하며 종양학 및 생식 유전 검사 발전을 강조합니다.
주요 제품으로는 MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, 및 Foresight Carrier Screen가 포함됩니다. Myriad는 부스 #317에서 전시하고, VUS 해석을 위한 RNA 분석, 초기 cfDNA 선별을 위한 태아 분획 증폭, 모체 대장암을 탐지하는 태아 cfDNA, FXN 반복의 자동 탐지, 유전 교육 및 재연 연락 워크플로우와 같은 주제의 포스터 발표를 공유합니다.
Myriad Genetics (NASDAQ: MYGN) présentera 11 nouvelles études de recherche à la 44e conférence annuelle de la National Society of Genetic Counselors les 7 et 8 novembre 2025, mettant en évidence les avancées des tests génétiques en oncologie et en reproduction.
Parmi les produits phares figurent MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen et Foresight Carrier Screen. Myriad exposera au stand booth #317 et partagera des présentations d'affiches sur des sujets tels que l'analyse de l'ARN pour l'interprétation des VUS, l'amplification de la fraction fœtale pour le dépistage précoce du cfDNA, le cfDNA prénatal détectant un cancer colorectal maternel, la détection automatisée des répétitions FXN, et l'éducation génétique et les flux de récontact.
Myriad Genetics (NASDAQ: MYGN) wird auf der 44. Jahreskonferenz der National Society of Genetic Counselors am 7.–8. November 2025 11 neue Forschungsstudien vorstellen und dabei Fortschritte bei genetischen Tests in Onkologie und Reproduktionsgenetik hervorheben.
Zu den vorgestellten Produkten gehören MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen und Foresight Carrier Screen. Myriad wird am Stand Booth #317 ausstellen und Poster-Präsentationen zu Themen wie RNA-Analyse zur Interpretation von VUS, Verstärkung der fötalen Fraktion für frühes cfDNA-Screening, pränataler cfDNA-Diagnose eines mütterlichen kolorektalen Krebs, automatisierte FXN-Wiederholungsdetektion sowie genetische Bildung und Recontact-Workflows teilen.
ميرياميد جينيتيكس (ناسداك: MYGN) ستقدم 11 دراسة بحثية جديدة في المؤتمر السنوي الأربعين للجمعية الوطنية لمستشاري الوراثة في 7-8 نوفمبر 2025، مع تسليط الضوء على التقدم في اختبارات الوراثة السرطانية والتناسلية.
تشمل المنتجات المميزة اختبار MYRisk للسرطان الوراثي، FirstGene Multiple Prenatal Screen، Prequel Prenatal Screen، وForesight Carrier Screen. ستعرض Myriad في الجناح رقم 317 وتتشارك عروض الملصقات حول مواضيع مثل تحليل الـ RNA لتفسير VUS، تضخيم نسبة الجنين من cfDNA للاختبار المبكر، cfDNA ما قبل الولادة يكشف عن سرطان القولون والمستقيم الأم، الكشف التلقائي عن تكرارات FXN، والتعليم الوراثي وتدفقات إعادة الاتصال.
- None.
- None.
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among the products included in the new studies to be shared.
“The data we’re presenting at NSGC demonstrates our ongoing commitment to advancing scientific research aimed at improving patient outcomes and delivering innovative products that provide timely, data-driven, actionable insights to inform more personalized patient care,” said Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics. “We’re excited to share this research with the genetic counseling community and to continue collaborating to help make genetic testing more accessible for all patients.”
Myriad’s latest innovations and support services will be on display at booth #317 and through a series of poster presentations throughout the conference.
Myriad’s presentation schedule
Friday, Nov. 7, 2025, at 5:15pm PT
- Poster #CAN103: RNA analysis from residual blood aids the interpretation of Variant of Uncertain Significance (VUS) identified in individuals undergoing hereditary cancer genetic testing
- Poster #GENT253: Fetal fraction amplification yields sufficient fetal fraction to enable cfDNA screening with a low screen-failure rate between 8-10 weeks gestation
- Poster #PRE365: Provider & patient uptake of prenatal cfDNA screening at an earlier gestational age
- Poster #PRE363: Prenatal cell-free DNA screening helps uncover maternal colorectal cancer: a case study
- Poster #GENT245: High-throughput, automated detection of FXN repeat expansions using repeat primed PCR followed by capillary electrophoresis
- Poster #PRE385: From concept to care: the evolution of a genetic screening report through clinical and design collaboration
- Poster #CAN083: The spectrum of germline hereditary cancer mutations within a laboratory-based research registry
- Poster #EDU161: Shaping the future: Evolving a field-based laboratory rotation to meet the needs of genetic counseling students
- Poster #EDU159: Genetic counseling student interest in GC roles in an industry rotation setting
Saturday, Nov. 8, 2025, at 5:00pm PT
- Poster #ASD018: Leveraging a longitudinal genomics platform to recontact patients eligible for Hereditary Cancer Genetic Testing
- Poster #PRO394: Professional development for seasoned genetic counselors: Moving from clinical expertise to leadership excellence
For more information about Myriad’s presence at NSGC, please visit: myriad.com/nsgc/. Updates will also be shared across Myriad’s LinkedIn and X channels throughout the conference.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the company’s ongoing commitment to scientific research and collaborations aimed at improving patient outcomes and expanding access to genetic testing. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
What will Myriad Genetics present at the NSGC 44th Annual Conference on Nov. 7–8, 2025 (MYGN)?
Which Myriad tests are included in the NSGC 2025 presentations (MYGN)?
When and where are Myriad poster presentations scheduled at NSGC 2025 (MYGN)?
Which Myriad poster covers early cfDNA screening success at NSGC 2025 (MYGN)?
Is Myriad sharing research on interpreting variants of uncertain significance (VUS) at NSGC 2025 (MYGN)?
Where can investors and clinicians find updates from Myriad at the NSGC conference (MYGN)?
